Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer

Cancer Invest. 2009 Jan;27(1):13-6. doi: 10.1080/07357900802484944.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / economics*
  • Breast Neoplasms / secondary
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Models, Economic
  • Time Factors

Substances

  • Antineoplastic Agents